Equities
  • Price (EUR)46.70
  • Today's Change0.300 / 0.65%
  • Shares traded--
  • 1 Year change+20.83%
  • Beta0.8640
Data delayed at least 15 minutes, as of Feb 06 2026 18:31 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

SOL SpA is an Italy-based company primarily engaged in the research, production and distribution of industrial, pure and medicinal gases. It is also involved in the home care medical business. The Company’s product portfolio includes oxygen, nitrogen, hydrogen, argon, sulfur hexafluoride, carbon dioxide, ozone, helium and mixtures of medicinal gases, among others. Through its subsidiaries, the Company is involved in the provision of home care services, such as oxygen therapy, mechanical ventilation, diagnosis and care of obstructive sleep apnea syndrome, artificial nutrition, telemedicine, health assistance, and the prevention and treatment of skin ulcers. Additionally, it is engaged in the supply and management of medical and technological devices for home care. As of December 31, 2011, the Company had a number of subsidiaries, including Airsol BV, Biotechsol Srl, CTS Srl, Energetika ZJ doo, GTH Gaze Industriale SA, Cryolab Srl, GTS Shpk and Hydroenergy Shpk, among others.

  • Revenue in EUR (TTM)1.70bn
  • Net income in EUR156.30m
  • Incorporated--
  • Employees7.41k
  • Location
    SOL SpAVia Borgazzi, 27MONZA 20900ItalyITA
  • Phone+39 3923961
  • Fax+39 392396265
  • Websitehttps://www.sol.it/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SOL:MIL since
announced
Transaction
value
Vitalaire Suisse SADeal completed20 Jan 202620 Jan 2026Deal completed-2.89%--
Data delayed at least 15 minutes, as of Feb 06 2026 16:35 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.